Exposure variance | Study group | TB cases, n (%) | Time to onset, median (range), weeks | PY | IR per 100 PY (95% CI) | HR (95% CI) | |
Unadjusted | Adjusted | ||||||
Window period of 6 months and follow-up for 5 years | bDMARD | 186 (1.4) | 43.3 (0.1–254.9) | 40 613 | 0.46 (0.39 to 0.52) | Reference | |
JAK inhibitor | 15 (0.4) | 51.1 (0.1–169.4) | 7883 | 0.19 (0.09 to 0.29) | 0.37 (0.22 to 0.62) | 0.37 (0.22 to 0.62) | |
Window period of 12 months and follow-up for 5 years | bDMARD | 192 (1.4) | 45.5 (0.1–254.9) | 43 722 | 0.44 (0.38 to 0.5) | Reference | |
JAK inhibitor | 15 (0.4) | 51.1 (0.1–169.4) | 8126 | 0.18 (0.09 to 0.28) | 0.37 (0.22 to 0.62) | 0.37 (0.22 to 0.62) | |
Window period of 12 months and follow-up until the end of the study | bDMARD | 199 (1.5) | 50.4 (0.1–483.0) | 50 836 | 0.39 (0.34 to 0.45) | Reference | |
JAK inhibitor | 15 (0.4) | 51.1 (0.1–169.4) | 7915 | 0.19 (0.09 to 0.29) | 0.37 (0.22 to 0.62) | 0.37 (0.22 to 0.63) | |
Window period of 12 months and follow-up until the end of the study | bDMARD | 207 (1.5) | 52.9 (0.1–483.0) | 55 089 | 0.38 (0.32 to 0.43) | Reference | |
JAK inhibitor | 15 (0.4) | 51.1 (0.1–169.4) | 8160 | 0.18 (0.09 to 0.28) | 0.37 (0.22 to 0.62) | 0.37 (0.22 to 0.63) |
bDMARD, biological disease-modifying antirheumatic drug; IR, incidence rate; JAK, Janus kinase; PY, person-year; RA, rheumatoid arthritis; TB, tuberculosis.